Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants

No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data

(2016) Ella T. Nkhoma et al.   MEDICINE

Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race

(2016) Paul Leger et al.   Pharmacogenetics and Genomics

Worth the Weight: Using Inverse Probability Weighted Cox Models in AIDS Research

(2014) Ashley L. Buchanan et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide

(2014) Katie R. Mollan et al.   ANNALS OF INTERNAL MEDICINE

Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes

(2014) David W. Haas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database

(2014) Andrew A Napoli et al.   Journal of the International AIDS Society

Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols

(2014) C. B. Moore et al.   Open Forum Infectious Diseases

Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

(2013) Eric S. Daar   ANNALS OF INTERNAL MEDICINE

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants

(2012) Emily R. Holzinger et al.   Pharmacogenetics and Genomics

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

(2012) Thomas B. Campbell et al.   PLOS MEDICINE

Splines for Trend Analysis and Continuous Confounder Control

(2011) Chanelle J. Howe et al.   EPIDEMIOLOGY

Review of inverse probability weighting for dealing with missing data

(2011) Shaun R Seaman et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection

(2010) David A. Cooper et al.   JOURNAL OF INFECTIOUS DISEASES

Effect ofCYP2B6,ABCB1, andCYP3A5Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study

(2010) Heather J. Ribaudo et al.   JOURNAL OF INFECTIOUS DISEASES

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

(2010)   SCIENCE

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

(2009) Awewura Kwara et al.   AIDS

CYP2B6(c.516G→T) andCYP2A6(*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients

(2009) Awewura Kwara et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine

(2009) A.-S. Belanger et al.   DRUG METABOLISM AND DISPOSITION

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

(2009) Julia di Iulio et al.   Pharmacogenetics and Genomics

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

(2008) C. Wyen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Class-Sparing Regimens for Initial Treatment of HIV-1 Infection

(2008) Sharon A. Riddler et al.   NEW ENGLAND JOURNAL OF MEDICINE